NASDAQ:CUE

Cue Biopharma Competitors

$11.50
-0.78 (-6.35 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.26
Now: $11.50
$12.26
50-Day Range
$11.20
MA: $13.22
$15.85
52-Week Range
$10.75
Now: $11.50
$31.69
Volume266,291 shs
Average Volume305,827 shs
Market Capitalization$350.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95

Competitors

Cue Biopharma (NASDAQ:CUE) Vs. CMPS, ZEAL, PMVP, KROS, ARQT, and TBPH

Should you be buying CUE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cue Biopharma, including COMPASS Pathways (CMPS), Zealand Pharma A/S (ZEAL), PMV Pharmaceuticals (PMVP), Keros Therapeutics (KROS), Arcutis Biotherapeutics (ARQT), and Theravance Biopharma (TBPH).

Cue Biopharma (NASDAQ:CUE) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares Cue Biopharma and COMPASS Pathways' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

COMPASS Pathways has lower revenue, but higher earnings than Cue Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Cue Biopharma and COMPASS Pathways, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
COMPASS Pathways00603.00

Cue Biopharma currently has a consensus price target of $31.25, indicating a potential upside of 171.74%. COMPASS Pathways has a consensus price target of $70.75, indicating a potential upside of 85.26%. Given Cue Biopharma's higher possible upside, equities analysts plainly believe Cue Biopharma is more favorable than COMPASS Pathways.

Profitability

This table compares Cue Biopharma and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
COMPASS PathwaysN/AN/AN/A

Institutional & Insider Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

COMPASS Pathways beats Cue Biopharma on 5 of the 9 factors compared between the two stocks.

Cue Biopharma (NASDAQ:CUE) and Zealand Pharma A/S (NASDAQ:ZEAL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Cue Biopharma and Zealand Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
Zealand Pharma A/S$6.20 million224.63$-85,670,000.00($2.54)-12.63

Cue Biopharma has higher earnings, but lower revenue than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Cue Biopharma and Zealand Pharma A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
Zealand Pharma A/S00203.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Zealand Pharma A/S has a consensus price target of $43.00, suggesting a potential upside of 34.00%. Given Cue Biopharma's higher probable upside, research analysts plainly believe Cue Biopharma is more favorable than Zealand Pharma A/S.

Profitability

This table compares Cue Biopharma and Zealand Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
Zealand Pharma A/S-214.31%-38.34%-30.40%

Volatility & Risk

Cue Biopharma has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cue Biopharma beats Zealand Pharma A/S on 8 of the 13 factors compared between the two stocks.

Cue Biopharma (NASDAQ:CUE) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Cue Biopharma and PMV Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
PMV PharmaceuticalsN/AN/AN/AN/AN/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Cue Biopharma.

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
PMV PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Cue Biopharma and PMV Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
PMV Pharmaceuticals01302.75

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. PMV Pharmaceuticals has a consensus price target of $38.00, suggesting a potential upside of 22.27%. Given Cue Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Cue Biopharma is more favorable than PMV Pharmaceuticals.

Summary

Cue Biopharma beats PMV Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Cue Biopharma (NASDAQ:CUE) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Keros Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
Keros TherapeuticsN/AN/AN/AN/AN/A

Keros Therapeutics has lower revenue, but higher earnings than Cue Biopharma.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 58.4% of Keros Therapeutics shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Keros Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
Keros TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Keros Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
Keros Therapeutics00403.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Keros Therapeutics has a consensus price target of $78.00, suggesting a potential upside of 32.90%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Keros Therapeutics.

Summary

Cue Biopharma beats Keros Therapeutics on 4 of the 7 factors compared between the two stocks.

Cue Biopharma (NASDAQ:CUE) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Arcutis Biotherapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.19

Cue Biopharma has higher revenue and earnings than Arcutis Biotherapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
Arcutis BiotherapeuticsN/A-81.74%-57.72%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Arcutis Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
Arcutis Biotherapeutics00403.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 101.72%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Arcutis Biotherapeutics.

Summary

Cue Biopharma beats Arcutis Biotherapeutics on 7 of the 10 factors compared between the two stocks.

Cue Biopharma (NASDAQ:CUE) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Theravance Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$3.46 million101.23$-36,700,000.00($1.66)-6.93
Theravance Biopharma$73.41 million18.26$-236,460,000.00($4.25)-4.84

Cue Biopharma has higher earnings, but lower revenue than Theravance Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cue Biopharma-1,142.70%-63.69%-50.08%
Theravance Biopharma-345.16%N/A-51.60%

Risk and Volatility

Cue Biopharma has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Theravance Biopharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cue Biopharma00403.00
Theravance Biopharma00703.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Theravance Biopharma has a consensus price target of $33.2857, suggesting a potential upside of 61.97%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Theravance Biopharma.

Summary

Cue Biopharma beats Theravance Biopharma on 7 of the 13 factors compared between the two stocks.


Cue Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$38.19-6.3%$1.40 billionN/A0.00
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.09-2.2%$1.39 billion$6.20 million-14.07
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.08-7.1%$1.39 billionN/A0.00
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$58.69-2.5%$1.37 billionN/A0.00
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.10-1.8%$1.36 billionN/A-2.94
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.55-1.9%$1.34 billion$73.41 million-4.34News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$28.46-8.9%$1.31 billion$29.54 million-7.55
Shattuck Labs logo
STTK
Shattuck Labs
1.4$30.75-8.2%$1.28 billionN/A0.00Lockup Expiration
News Coverage
OLMA
Olema Pharmaceuticals
1.6$31.73-3.5%$1.27 billionN/A0.00
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.20-1.9%$1.23 billion$4.23 million-9.05
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$33.04-4.0%$1.21 billionN/A-18.36
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.46-5.2%$1.20 billionN/A0.00
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.00-1.3%$1.19 billionN/A-2.72
Innoviva logo
INVA
Innoviva
1.4$11.67-0.3%$1.18 billion$261.02 million5.95
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.95-1.4%$1.16 billionN/A0.00Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$18.93-2.4%$1.15 billion$59.70 million-189.30
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.22-1.4%$1.15 billion$230,000.00-12.20News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.33-0.2%$1.15 billionN/A-8.87News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-0.0%$1.14 billion$35.22 million-7.35
NKTX
Nkarta
1.8$34.01-5.1%$1.12 billionN/A0.00News Coverage
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.15-9.5%$1.10 billionN/A-6.81News Coverage
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.70-10.4%$1.10 billion$57.05 million0.00
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.86-0.3%$1.10 billion$42.12 million-11.75
Zogenix logo
ZGNX
Zogenix
1.7$18.93-1.8%$1.06 billion$3.65 million-1.99Analyst Upgrade
News Coverage
Omeros logo
OMER
Omeros
1.4$16.93-7.7%$1.05 billion$111.81 million-7.11
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.84-3.0%$1.05 billionN/A-8.06
MannKind logo
MNKD
MannKind
1.4$4.18-1.4%$1.04 billion$63.04 million-19.90
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.27-4.2%$1.03 billion$1.52 million-11.31
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.32-4.7%$1.02 billionN/A-6.68
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.87-5.6%$1.02 billion$120,000.00-3.66
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.75-7.7%$996.53 millionN/A-8.19Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.48-0.6%$977.94 million$122.47 million-26.64
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.15-1.6%$976.94 million$800.40 million22.78News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$36.99-0.0%$972.10 million$20.79 million-12.76Analyst Upgrade
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.01-2.8%$939.14 millionN/A-12.45Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$27.23-4.2%$919.83 millionN/A-25.21News Coverage
Annexon logo
ANNX
Annexon
1.9$23.25-7.2%$887.17 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$18.90-3.1%$886.30 million$173.32 million-7.75News Coverage
Prothena logo
PRTA
Prothena
2.3$21.91-4.0%$876.53 million$810,000.00-8.56
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$15.92-2.1%$873.74 million$227.19 million44.22Analyst Upgrade
Merus logo
MRUS
Merus
1.6$22.83-1.0%$870.44 million$31.13 million-7.44Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.07-2.3%$861.78 millionN/A-10.41Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.70-0.3%$859.35 millionN/A0.00News Coverage
Affimed logo
AFMD
Affimed
1.6$9.65-0.9%$852.35 million$23.96 million-16.36Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Humanigen logo
HGEN
Humanigen
1.7$15.80-9.2%$845.02 millionN/A0.00Analyst Report
Epizyme logo
EPZM
Epizyme
1.8$8.12-3.1%$826.49 million$23.80 million-3.64
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.11-4.6%$811.58 million$322.36 million122.21
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.79-2.4%$802.30 million$296.70 million46.51News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.96-0.6%$747.61 million$40.89 million-3.43Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.07-5.9%$731.88 million$322.07 million-4.83
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.